SWX:NOVNPharmaceuticals
Is Novartis’ US Radioligand Manufacturing Buildout (SWX:NOVN) Altering Its Investment Case?
In early May 2026, Novartis broke ground on a new 46,000 sq. ft radioligand therapy manufacturing facility in Denton, Texas, part of its US$23.00 billion US manufacturing and research expansion and its fifth radioligand therapy site nationwide.
This build-out of a coast-to-coast radioligand therapy network highlights how Novartis is tying manufacturing proximity and reliability directly to complex cancer treatment delivery for US patients.
We will now explore how this expanded US radioligand...